Pulse Biosciences' 2027 Trial Readout Crucial to Evaluate New Pulsed Field Ablation Modality, Oppenheimer Says

12:40 PM EDT, 10/13/2026 (MT Newswires) -- Pulse Biosciences' (PLSE) strategic value is highlighted by competitors' stumbles, but much remains to be learned about the nanosecond pulsed field ablation, making the 2027 pivotal trial readout crucial to assessing the new PFA modality and nsPFA's role in the competitive landscape, Oppenheimer said Tuesday in a note. The company's Nanopulse-AF single-arm study has completed enrollment, and while its argument of quicker and more reproducible technique remains compelling at face value, the "durability of lesion sets" will ultimately determine its success, according to the note. While performance target for the pivotal study remains unclear, implicit Street expectations call for patients to remain free from atrial fibrillation or atrial flutter for 12 months without antiarrhythmics, the note added. The brokerage noted that event rate percentages with VOLT 2.0 are increasing, especially perforations and deaths. It remains unclear if there is a product design or technique issue, it added. Oppenheimer kept an outperform rating on Pulse Biosciences and raised its price target to $60 per share from $35. Shares of Pulse Biosciences were down 5.7% in Tuesday trading. Price: 49.48, Change: -2.98, Percent Change: -5.67